Getinge Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Getinge heeft een totaal eigen vermogen van SEK30.5B en een totale schuld van SEK9.1B, wat de schuld-eigenvermogensverhouding op 30% brengt. De totale activa en totale passiva bedragen respectievelijk SEK59.6B en SEK29.1B. De EBIT Getinge is SEK3.4B waardoor de rentedekking 6.8 is. Het heeft contanten en kortetermijnbeleggingen van SEK2.2B.

Belangrijke informatie

30.0%

Verhouding schuld/eigen vermogen

SEK 9.13b

Schuld

Rente dekkingsratio	6.8x
Contant	SEK 2.24b
Aandelen	SEK 30.47b
Totaal verplichtingen	SEK 29.15b
Totaal activa	SEK 59.61b

Recente financiële gezondheidsupdates

Recent updates

Does Getinge (STO:GETI B) Have A Healthy Balance Sheet?

Jan 03

Getinge AB (publ)'s (STO:GETI B) Price In Tune With Earnings

Dec 05

Getinge (STO:GETI B) Is Experiencing Growth In Returns On Capital

Oct 17

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Sep 19

Pinning Down Getinge AB (publ)'s (STO:GETI B) P/E Is Difficult Right Now

Aug 23

An Intrinsic Calculation For Getinge AB (publ) (STO:GETI B) Suggests It's 49% Undervalued

Aug 08

Getinge AB (publ) Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

Jul 21

We Like These Underlying Return On Capital Trends At Getinge (STO:GETI B)

Jun 27

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

May 11

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 25

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

Apr 15

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 29

The Return Trends At Getinge (STO:GETI B) Look Promising

Mar 21

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Feb 04

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Jan 20

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Jan 05

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Dec 20

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Dec 05

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 06

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Sep 21

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Sep 03

Is Getinge (STO:GETI B) A Risky Investment?

Jun 28

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Jun 15

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

Jun 01

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

May 05

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Apr 05

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Feb 28

Is Getinge AB (publ) (STO:GETI B) Trading At A 42% Discount?

Feb 16

Getinge (STO:GETI B) Is Paying Out A Larger Dividend Than Last Year

Feb 04

Is Getinge (STO:GETI B) Using Too Much Debt?

Feb 03

When Should You Buy Getinge AB (publ) (STO:GETI B)?

Jan 07

Are Investors Undervaluing Getinge AB (publ) (STO:GETI B) By 49%?

Nov 06

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 07

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK16.3B ) GETI B } overtreffen de korte termijn passiva ( SEK15.2B ).

Langlopende schulden: De kortetermijnactiva GETI B ( SEK16.3B ) overtreffen de langetermijnschulden ( SEK13.9B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 22.6% ) GETI B wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van GETI B is de afgelopen 5 jaar gedaald van 50.9% naar 30%.

Schuldendekking: De schuld van GETI B wordt goed gedekt door de operationele kasstroom ( 42.3% ).

Rentedekking: De rentebetalingen op de schuld van GETI B worden goed gedekt door EBIT ( 6.8 x dekking).

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/10 00:21
Aandelenkoers aan het einde van de dag	2025/01/10 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Getinge AB (publ) wordt gevolgd door 33 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Sten Gustafsson	ABG Sundal Collier
Kamla Singh	AlphaValue
Scott Bardo	Berenberg

Getinge Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Getinge (STO:GETI B) Have A Healthy Balance Sheet?

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Is Getinge (STO:GETI B) A Risky Investment?

Recent updates

Does Getinge (STO:GETI B) Have A Healthy Balance Sheet?

Independent Director recently bought kr1.0m worth of stock

Independent Director recently bought kr670k worth of stock

Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025

Getinge AB (publ)'s (STO:GETI B) Price In Tune With Earnings

Getinge AB (Publ) Announces Changes of the Nomination Committee

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Independent Director recently bought kr473k worth of stock

Consensus EPS estimates fall by 11%

Non-Independent Director recently bought kr621k worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Getinge (STO:GETI B) Is Experiencing Growth In Returns On Capital

Independent Director recently bought kr1.1m worth of stock

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought kr4.3m worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Pinning Down Getinge AB (publ)'s (STO:GETI B) P/E Is Difficult Right Now

An Intrinsic Calculation For Getinge AB (publ) (STO:GETI B) Suggests It's 49% Undervalued

Getinge AB (publ) Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

We Like These Underlying Return On Capital Trends At Getinge (STO:GETI B)

Investor sentiment deteriorates as stock falls 18%

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

The Return Trends At Getinge (STO:GETI B) Look Promising

Dividend increased to kr4.40

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Price target increased by 8.4% to kr229

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Price target increased by 7.0% to kr220

Consensus EPS estimates increase by 23%

Third quarter 2023 earnings: Revenues exceed analyst expectations

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Second quarter 2023 earnings: Revenues exceed analyst expectations

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Is Getinge (STO:GETI B) A Risky Investment?

Consensus EPS estimates fall by 13%

Investor sentiment deteriorates as stock falls 22%

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

First quarter 2023 earnings: Revenues exceed analyst expectations

Now 22% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement